axicabtagene ciloleucel,tisagenlecleucel
novartis,gilead,daiichi sankyo
['tisa cel']
cd19 car-t (axi and tisa cel) for richters #ash22 crr 42% in n=12 short follow up (1.6 months) but response rates are promising
strong responses in a very challenging cohort 
Bone marrow doctor????
ACF #Haematology 
MRC CRTF @uclcancer Roddie/Pule lab 
@theEBMT_Trainee committee member 
#CARTcell #MPN #translational_research ????????